Dr. Robert Fishman joins 4D molecular Therapeutics (4DMT) as its Chief Medical Officer. As a member of 4DMT’s Executive Team, Dr. Fishman will be responsible for Clinical Operations and Clinical Research. Dr. Fishman most recently worked at Xoc Pharmaceuticals, where he led IND submissions and Phase 1 studies for prevention of migraine and treatment of Parkinson’s disease. He has over 20 years of experience in product development spanning drugs and drug-device combinations. At InterMune (acquired by Roche), he led the final pivotal trial of pirfenidone (Esbriet®) for the treatment of idiopathic pulmonary fibrosis. At Alexza Pharmaceuticals, he led the Phase 3 studies of inhaled loxapine (ADASUVE®), a drug/device combination for the rapid treatment of agitation associated with schizophrenia or bipolar I disorder.
Dr. Fishman trained in internal medicine at Deaconess Hospital, Boston, completed a fellowship in pulmonary and critical care medicine at Massachusetts General Hospital, and began his career as a member of the Stanford University pulmonary medicine faculty. He serves as a teaching attending physician in the Stanford pulmonary fellows’ clinic at Palo Alto Veterans Administration Medical Center, and as an advisor to the Stanford SPARK Program in Translational Research. He earned an A.B. in Biology from Harvard University and an M.D. from Stanford University School of Medicine.